{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T07:13:09Z","timestamp":1772089989310,"version":"3.50.1"},"reference-count":108,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Vascular Surgery"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1053\/j.semvascsurg.2022.04.003","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T21:00:34Z","timestamp":1649797234000},"page":"113-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Medical optimization of the peripheral artery disease patient"],"prefix":"10.1053","volume":"35","author":[{"given":"James M.","family":"Dittman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael F.","family":"Amendola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kedar S.","family":"Lavingia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0001","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCULATIONAHA.110.003954","article-title":"Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004","volume":"124","author":"Pande","year":"2011","journal-title":"Circulation"},{"issue":"5","key":"10.1053\/j.semvascsurg.2022.04.003_bib0002","doi-asserted-by":"crossref","first-page":"e721","DOI":"10.1016\/S2214-109X(20)30117-0","article-title":"Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modelling study","volume":"8","author":"Song","year":"2020","journal-title":"Lancet Glob Health"},{"issue":"8","key":"10.1053\/j.semvascsurg.2022.04.003_bib0003","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics-2021 update: a report from the American Heart Association","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0004","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1161\/CIR.0000000000001005","article-title":"Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American Heart Association","volume":"144","author":"Criqui","year":"2021","journal-title":"Circulation"},{"issue":"3 suppl","key":"10.1053\/j.semvascsurg.2022.04.003_bib0005","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1016\/j.jvs.2014.12.009","article-title":"Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication","volume":"61","author":"Conte","year":"2015","journal-title":"J Vasc Surg"},{"issue":"1S","key":"10.1053\/j.semvascsurg.2022.04.003_bib0006","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ejvs.2019.05.006","article-title":"Global vascular guidelines on the management of chronic limb-threatening ischemia","volume":"58","author":"Conte","year":"2019","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0007","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1161\/ATVBAHA.119.312142","article-title":"Evidence-based medical management of peripheral artery disease","volume":"40","author":"Bevan","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0008","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/ehjqcco\/qcaa052","article-title":"Patient profiles and health status outcomes for peripheral artery disease in high-income countries: a comparison between the USA and The Netherlands","volume":"7","author":"Jelani","year":"2021","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0009","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.286.11.1317","article-title":"Peripheral arterial disease detection, awareness, and treatment in primary care","volume":"286","author":"Hirsch","year":"2001","journal-title":"JAMA"},{"issue":"suppl 2","key":"10.1053\/j.semvascsurg.2022.04.003_bib0010","doi-asserted-by":"crossref","first-page":"II19","DOI":"10.1177\/15266028060130S206","article-title":"Medical management of peripheral arterial disease: a therapeutic algorithm","volume":"13","author":"Lumsden","year":"2006","journal-title":"J Endovasc Ther"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0011","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jama.2018.4250","article-title":"Screening for peripheral artery disease using the ankle-brachial index: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"320","author":"Guirguis-Blake","year":"2018","journal-title":"JAMA"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0012","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/1538574406291835","article-title":"Optimal medical management of peripheral arterial disease","volume":"40","author":"Rice","year":"2006","journal-title":"Vasc Endovasc Surg"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0013","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jacc.2019.05.049","article-title":"Cigarette smoking, smoking cessation, and long-term risk of 3 major atherosclerotic diseases","volume":"74","author":"Ding","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0014","first-page":"189","article-title":"The relationship of cigarette smoking to peripheral arterial disease","volume":"5","author":"Lu","year":"2004","journal-title":"Rev Cardiovasc Med"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0015","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5694\/j.1326-5377.1983.tb99395.x","article-title":"The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease","volume":"1","author":"Faulkner","year":"1983","journal-title":"Med J Aust"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0016","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.jvs.2018.07.027","article-title":"Medical and lifestyle management of peripheral arterial disease","volume":"68","author":"Parvar","year":"2018","journal-title":"J Vasc Surg"},{"issue":"10037","key":"10.1053\/j.semvascsurg.2022.04.003_bib0017","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/S0140-6736(16)30272-0","article-title":"Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial","volume":"387","author":"Anthenelli","year":"2016","journal-title":"Lancet"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0018","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1331\/JAPhA.2008.07063","article-title":"Systematic review and meta-analysis of combination therapy for smoking cessation","volume":"48","author":"Shah","year":"2008","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"20","key":"10.1053\/j.semvascsurg.2022.04.003_bib0019","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010076","article-title":"Underutilization of evidence-based smoking cessation support strategies despite high smoking addiction burden in peripheral artery disease specialty care: insights from the international PORTRAIT Registry","volume":"7","author":"Patel","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0020","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/j.jacc.2010.07.031","article-title":"Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial","volume":"56","author":"Hennrikus","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1053\/j.semvascsurg.2022.04.003_bib0021","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0004-9514(14)60166-5","article-title":"Improving maximum walking distance in early peripheral arterial disease: randomised controlled trial","volume":"48","author":"Fowler","year":"2002","journal-title":"Aust J Physiother"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0022","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.avsg.2018.09.017","article-title":"Successful smoking cessation associated with walking behavior in patients with claudication","volume":"56","author":"Sharath","year":"2019","journal-title":"Ann Vasc Surg"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0023","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/ejvs.2000.1294","article-title":"Coagulation, fibrinolysis and platelet P-selectin expression in peripheral vascular disease","volume":"21","author":"Koksch","year":"2001","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0024","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1055\/s-0032-1330232","article-title":"A review of the role of anticoagulation in the treatment of peripheral arterial disease","volume":"21","author":"Whayne","year":"2012","journal-title":"Int J Angiol"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0025","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jama.2010.221","article-title":"Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial","volume":"303","author":"Fowkes","year":"2010","journal-title":"JAMA"},{"issue":"7329","key":"10.1053\/j.semvascsurg.2022.04.003_bib0026","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Collaboration","year":"2002","journal-title":"BMJ"},{"issue":"9038","key":"10.1053\/j.semvascsurg.2022.04.003_bib0027","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"Steering Committee","year":"1996","journal-title":"Lancet"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0028","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1001\/jama.2018.5422","article-title":"Antithrombotic therapy for peripheral artery disease in 2018","volume":"319","author":"Hess","year":"2018","journal-title":"JAMA"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0029","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1161\/CIRCULATIONAHA.109.895342","volume":"121","author":"Berger","year":"2010","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa065959","article-title":"Oral anticoagulant and antiplatelet therapy and peripheral arterial disease","volume":"357","author":"Anand","year":"2007","journal-title":"N Engl J Med"},{"issue":"10117","key":"10.1053\/j.semvascsurg.2022.04.003_bib0031","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0032","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0033","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.116.024637","volume":"134","author":"Bonaca","year":"2016","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0034","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1007\/s00330-012-2441-2","article-title":"Management of peripheral arterial interventions with mono or dual antiplatelet therapy\u2014the MIRROR study: a randomised and double-blinded clinical trial","volume":"22","author":"Tepe","year":"2012","journal-title":"Eur Radiol"},{"issue":"825-33","key":"10.1053\/j.semvascsurg.2022.04.003_bib0035","first-page":"e1","article-title":"Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial","volume":"52","author":"Belch","year":"2010","journal-title":"J Vasc Surg"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0036","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","article-title":"Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease","volume":"67","author":"Bonaca","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0037","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.3390\/biomedicines9091280","article-title":"Reinitiation and subsequent discontinuation of antiplatelet treatment in nonpersistent older patients with peripheral arterial disease","volume":"9","author":"Wawruch","year":"2021","journal-title":"Biomedicines"},{"issue":"9326","key":"10.1053\/j.semvascsurg.2022.04.003_bib0038","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"Heart Protection Study Collaborative Group. MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1053\/j.semvascsurg.2022.04.003_bib0039","article-title":"Lipid-lowering for peripheral arterial disease of the lower limb","author":"Aung","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0040","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0041","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1161\/CIRCULATIONAHA.117.033092","article-title":"Statins in PAD: what are we waiting for?","volume":"137","author":"Aday","year":"2018","journal-title":"Circulation"},{"issue":"suppl S","key":"10.1053\/j.semvascsurg.2022.04.003_bib0042","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","article-title":"Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)","volume":"45","author":"Norgren","year":"2007","journal-title":"J Vasc Surg"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0043","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0044","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jvs.2018.07.089","article-title":"Statin use improves limb salvage after intervention for peripheral arterial disease","volume":"70","author":"Parmar","year":"2019","journal-title":"J Vasc Surg"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0045","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jvs.2007.01.024","article-title":"The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease","volume":"45","author":"Feringa","year":"2007","journal-title":"J Vasc Surg"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0046","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0047","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/nrcardio.2012.117","article-title":"The role of nutrition and body composition in peripheral arterial disease","volume":"9","author":"Brostow","year":"2012","journal-title":"Nat Rev Cardiol"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0048","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1001\/jama.2013.280618","article-title":"Association of Mediterranean diet with peripheral artery disease: the PREDIMED randomized trial","volume":"311","author":"Ruiz-Canela","year":"2014","journal-title":"JAMA"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0049","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jvs.2014.10.022","article-title":"Advancing beyond the \u2018heart-healthy diet\u2019 for peripheral arterial disease","volume":"61","author":"Nosova","year":"2015","journal-title":"J Vasc Surg"},{"issue":"3","key":"10.1053\/j.semvascsurg.2022.04.003_bib0050","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jvs.2011.07.031","article-title":"Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease","volume":"54","author":"Ricotta","year":"2011","journal-title":"J Vasc Surg"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0051","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1161\/CIRCRESAHA.116.303849","article-title":"Epidemiology of peripheral artery disease","volume":"116","author":"Criqui","year":"2015","journal-title":"Circ Res"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0052","doi-asserted-by":"crossref","first-page":"961","DOI":"10.4239\/wjd.v6.i7.961","article-title":"Peripheral artery disease in patients with diabetes: epidemiology, mechanisms, and outcomes","volume":"6","author":"Thiruvoipati","year":"2015","journal-title":"World J Diabetes"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0053","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1161\/01.CIR.0000091257.27563.32","article-title":"Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I","volume":"108","author":"Creager","year":"2003","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0054","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S2213-8587(18)30079-2","article-title":"Asia Pacific Cohort Studies Collaboration. Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies","volume":"6","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0055","doi-asserted-by":"crossref","first-page":"421","DOI":"10.7326\/0003-4819-141-6-200409210-00007","article-title":"Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus","volume":"141","author":"Selvin","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0056","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12933-014-0147-2","article-title":"Association of impaired fasting glucose, diabetes and their management with the presentation and outcome of peripheral artery disease: a cohort study","volume":"13","author":"Golledge","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"10.1053\/j.semvascsurg.2022.04.003_bib0057","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008143.pub3","article-title":"Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus","author":"Hemmingsen","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0058","doi-asserted-by":"crossref","first-page":"13","DOI":"10.22374\/cjgim.v14i2.282","article-title":"Oral hypoglycemics in patients with type 2 diabetes and peripheral artery disease","volume":"14","author":"Rannelli","year":"2019","journal-title":"Can J Gen Intern Med"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0059","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1161\/CIRCULATIONAHA.117.032031","article-title":"Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME","volume":"137","author":"Verma","year":"2018","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0060","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0061","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S2213-8587(17)30257-7","article-title":"SGLT2 inhibitors and amputations in the US FDA adverse event reporting system","volume":"5","author":"Fadini","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1053\/j.semvascsurg.2022.04.003_bib0062","first-page":"e0118","article-title":"Foot care for patients with peripheral vascular disease: a review of the guidelines","volume":"1","year":"2010","journal-title":"CADTH Technol Overv"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0063","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.2174\/1381612043382819","article-title":"Hypertension in peripheral arterial disease","volume":"10","author":"Clement","year":"2004","journal-title":"Curr Pharm Des"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0064","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.2147\/VHRM.S3096","article-title":"Peripheral artery disease: potential role of ACE-inhibitor therapy","volume":"4","author":"Coppola","year":"2008","journal-title":"Vasc Health Risk Manag"},{"issue":"6","key":"10.1053\/j.semvascsurg.2022.04.003_bib0065","article-title":"Effect of blood pressure lowering medications on leg ischemia in peripheral artery disease patients: a meta-analysis of randomised controlled trials","volume":"12","author":"Manapurathe","year":"2017","journal-title":"PLoS One"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0066","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.coph.2018.01.009","article-title":"Anti-hypertensive treatment in peripheral artery disease","volume":"39","author":"Tsioufis","year":"2018","journal-title":"Curr Opin Pharmacol"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0067","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jacc.2016.11.008","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"69","author":"Gerhard-Herman","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"6018","key":"10.1053\/j.semvascsurg.2022.04.003_bib0068","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1136\/bmj.1.6018.1125","article-title":"Intermittent claudication complicating beta-blockade","volume":"1","author":"Rodger","year":"1976","journal-title":"Br Med J"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0069","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJM198005083021914","article-title":"Exacerbation of intermittent claudication by propranolol","volume":"302","author":"Fogoros","year":"1980","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.semvascsurg.2022.04.003_bib0070","article-title":"Beta blockers for peripheral arterial disease","author":"Paravastu","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1053\/j.semvascsurg.2022.04.003_bib0071","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1161\/CIRCULATIONAHA.106.174526","volume":"113","author":"Hirsch","year":"2006","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0072","doi-asserted-by":"crossref","first-page":"1","DOI":"10.31189\/2165-6193-8.1.1","article-title":"Experience implementing supervised exercise therapy for peripheral artery disease","volume":"8","author":"Salisbury","year":"2019","journal-title":"J Clin Exerc Physiol"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0073","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019672","article-title":"Network meta-analysis comparing the outcomes of treatments for intermittent claudication tested in randomized controlled trials","volume":"10","author":"Thanigaimani","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0074","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jacc.2014.12.043","article-title":"Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study","volume":"65","author":"Murphy","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0075","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jvs.2008.06.016","article-title":"Cost-effectiveness of endovascular revascularization compared to supervised hospital-based exercise training in patients with intermittent claudication: a randomized controlled trial","volume":"48","author":"Spronk","year":"2008","journal-title":"J Vasc Surg"},{"issue":"4","key":"10.1053\/j.semvascsurg.2022.04.003_bib0076","article-title":"Supervised exercise therapy versus home-based exercise therapy versus walking advice for intermittent claudication","volume":"4","author":"Hageman","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0077","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/bjs.7656","article-title":"Systematic review of exercise training or percutaneous transluminal angioplasty for intermittent claudication","volume":"99","author":"Frans","year":"2012","journal-title":"Br J Surg"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0078","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/bjs.10324","article-title":"Long-term outcomes of a randomized clinical trial of supervised exercise, percutaneous transluminal angioplasty or combined treatment for patients with intermittent claudication due to femoropopliteal disease","volume":"104","author":"Mazari","year":"2017","journal-title":"Br J Surg"},{"issue":"3","key":"10.1053\/j.semvascsurg.2022.04.003_bib0079","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012541","article-title":"Adherence to guideline-recommended therapy-including supervised exercise therapy referral-across peripheral artery disease specialty clinics: insights from the International PORTRAIT Registry","volume":"9","author":"Saxon","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0080","unstructured":"Centers for Medicare and Medicaid Services. Supervised exercise therapy (SET) for symptomatic peripheral artery disease (PAD). Accessed February 6, 2022. https:\/\/www.cms.gov\/medicare-coverage-database\/view\/ncacal-decision-memo.aspx?proposed=N&NCAId=287."},{"issue":"8","key":"10.1053\/j.semvascsurg.2022.04.003_bib0081","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.121.007953","article-title":"Supervised exercise therapy for symptomatic peripheral artery disease among Medicare beneficiaries between 2017 and 2018: participation rates and outcomes","volume":"14","author":"Divakaran","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0082","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/j.jvs.2019.08.238","article-title":"National assessment of availability, awareness, and utilization of supervised exercise therapy for peripheral artery disease patients with intermittent claudication","volume":"71","author":"Dua","year":"2020","journal-title":"J Vasc Surg"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0083","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.avsg.2016.02.009","article-title":"A systematic review of the uptake and adherence rates to supervised exercise programs in patients with intermittent claudication","volume":"34","author":"Harwood","year":"2016","journal-title":"Ann Vasc Surg"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0084","unstructured":"Society for Vascular Surgery. Society for Vascular Surgery and Cell-Ed Partner to launch pilot of SVS SET: a mobile exercise therapy app that may prevent and delay progression of peripheral artery disease. Accessed February 6, 2022. https:\/\/vascular.org\/news-advocacy\/society-vascular-surgery-and-cell-ed-partner-launch-pilot-svs-set-mobile-exercise."},{"issue":"8","key":"10.1053\/j.semvascsurg.2022.04.003_bib0085","doi-asserted-by":"crossref","first-page":"e24214","DOI":"10.2196\/24214","article-title":"Supervised exercise therapy using mobile health technology in patients with peripheral arterial disease: pilot randomized controlled trial","volume":"9","author":"Pald\u00e1n","year":"2021","journal-title":"JMIR Mhealth Uhealth"},{"issue":"6","key":"10.1053\/j.semvascsurg.2022.04.003_bib0086","article-title":"Cilostazol for intermittent claudication","volume":"6","author":"Brown","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0087","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1468-2982.2006.01218.x","article-title":"The headache-inducing effect of cilostazol in human volunteers","volume":"26","author":"Birk","year":"2006","journal-title":"Cephalalgia"},{"issue":"Pt 11","key":"10.1053\/j.semvascsurg.2022.04.003_bib0088","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1093\/brain\/awu244","article-title":"Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase","volume":"137","author":"Guo","year":"2014","journal-title":"Brain"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0089","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s10194-018-0841-7","article-title":"Cilostazol induced migraine does not respond to sumatriptan in a double blind trial","volume":"19","author":"Falkenberg","year":"2018","journal-title":"J Headache Pain"},{"issue":"1","key":"10.1053\/j.semvascsurg.2022.04.003_bib0090","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s10194-018-0890-y","article-title":"Pre-treatment with sumatriptan for cilostazol induced headache in healthy volunteers","volume":"19","author":"Falkenberg","year":"2018","journal-title":"J Headache Pain"},{"issue":"10","key":"10.1053\/j.semvascsurg.2022.04.003_bib0091","article-title":"Pentoxifylline for intermittent claudication","volume":"10","author":"Broderick","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0092","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0002-9343(03)00010-X","article-title":"Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease","volume":"114","author":"Mondillo","year":"2003","journal-title":"Am J Med"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0093","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1161\/01.CIR.0000090686.57897.F5","article-title":"Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease","volume":"108","author":"Mohler","year":"2003","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0094","first-page":"235","article-title":"Present and potential use of spinal cord stimulation to control chronic pain","volume":"17","author":"Song","year":"2014","journal-title":"Pain Physician"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0095","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/1358863X14552096","article-title":"A systematic review of intermittent pneumatic compression for critical limb ischaemia","volume":"20","author":"Moran","year":"2015","journal-title":"Vasc Med"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0096","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.jvs.2013.08.094","article-title":"New insights into the physiologic basis for intermittent pneumatic limb compression as a therapeutic strategy for peripheral artery disease","volume":"58","author":"Sheldon","year":"2013","journal-title":"J Vasc Surg"},{"issue":"12","key":"10.1053\/j.semvascsurg.2022.04.003_bib0097","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225950","article-title":"The long-term arterial assist intermittent pneumatic compression generating venous flow obstruction is responsible for improvement of arterial flow in ischemic legs","volume":"14","author":"Zaleska","year":"2019","journal-title":"PLoS One"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0098","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1177\/0003319719889273","article-title":"Prostanoids for critical limb ischemia: a clinical review and consideration of current guideline recommendations","volume":"71","author":"Meini","year":"2020","journal-title":"Angiology"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0099","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3390\/jcm7120548","article-title":"Hyperbaric oxygen therapy enhanced circulating levels of endothelial progenitor cells and angiogenesis biomarkers, blood flow, in ischemic areas in patients with peripheral arterial occlusive disease","volume":"7","author":"Lin","year":"2018","journal-title":"J Clin Med"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0100","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2337\/dc17-0654","article-title":"Hyperbaric oxygen therapy in the treatment of ischemic lower-extremity ulcers in patients with diabetes: results of the DAMO 2 CLES multicenter randomized clinical trial","volume":"41","author":"Santema","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0101","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jvs.2019.07.082","article-title":"A systematic review and meta-analysis of hyperbaric oxygen therapy for diabetic foot ulcers with arterial insufficiency","volume":"71","author":"Brouwer","year":"2020","journal-title":"J Vasc Surg"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0102","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1161\/ATVBAHA.120.312862","article-title":"Vascular regeneration in peripheral artery disease","volume":"40","author":"Cooke","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0103","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.ejvs.2015.08.018","article-title":"Bone marrow derived cell therapy in critical limb ischemia: a meta-analysis of randomized placebo controlled trials","volume":"50","author":"Peeters Weem","year":"2015","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0104","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1161\/CIRCRESAHA.116.309045","article-title":"Autologous cell therapy for peripheral arterial disease: systematic review and meta-analysis of randomized, nonrandomized, and noncontrolled studies","volume":"120","author":"Rigato","year":"2017","journal-title":"Circ Res"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0105","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.ejvs.2020.07.074","article-title":"Successful implementation of the exercise first approach for intermittent claudication in the Netherlands is associated with few lower limb revascularisations","volume":"60","author":"Jansen","year":"2020","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0106","article-title":"Long-term follow-up of a randomized clinical trial comparing endovascular revascularization plus supervised exercise with supervised exercise only for intermittent claudication [published online ahead of print December 23, 2020]","author":"Klaphake","year":"2020","journal-title":"Ann Surg"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0107","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/SLA.0000000000004073","article-title":"The effect of arterial disease level on outcomes of supervised exercise therapy for intermittent claudication: a prospective cohort study","volume":"275","author":"van den Houten","year":"2022","journal-title":"Ann Surg"},{"key":"10.1053\/j.semvascsurg.2022.04.003_bib0108","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ejvs.2021.09.042","article-title":"Randomised clinical trial of supervised exercise therapy vs. endovascular revascularisation for intermittent claudication caused by iliac artery obstruction: the SUPER study","volume":"63","author":"Koelemay","year":"2022","journal-title":"Eur J Vasc Endovasc Surg"}],"container-title":["Seminars in Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895796722000175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895796722000175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T05:38:55Z","timestamp":1760247535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0895796722000175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":108,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0895796722000175"],"URL":"https:\/\/doi.org\/10.1053\/j.semvascsurg.2022.04.003","relation":{},"ISSN":["0895-7967"],"issn-type":[{"value":"0895-7967","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical optimization of the peripheral artery disease patient","name":"articletitle","label":"Article Title"},{"value":"Seminars in Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semvascsurg.2022.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}